E-pharmacy and telehealth platform Truemeds secured $85 million in Series C funding to accelerate its expansion into smaller cities and towns across India. The Mumbai-based company closed the round in two tranches, with Accel leading the first and Peak XV Partners leading the second. Existing investors WestBridge Capital and Info Edge Ventures also increased their commitments.
The funding includes $65 million in fresh capital to power growth initiatives and $20 million in secondary transactions, allowing some early stakeholders to book partial profits.
Aggressive Push into Underserved Markets
Truemeds currently operates 19 fulfillment centers across India. The leadership plans to scale this network to 50 centers within the next year. This aggressive rollout targets high-demand non-metro locations, where patients often struggle to access affordable medicines and reliable delivery services.
The company aims to triple its national reach through these new fulfillment centers. Each facility will act as a regional distribution hub, cutting delivery times and improving inventory efficiency for chronic care patients.
In addition to medicines, Truemeds plans to launch pilot diagnostic services in four cities within the next two quarters. These diagnostic offerings will integrate with the company’s telehealth services, enabling patients to get tests, consult doctors, and receive medications in one seamless process.
Building a Stronger Tech Backbone
Truemeds wants to solidify its competitive advantage through technology. The leadership will hire top-tier engineering and product professionals, focusing on creating smarter, faster, and more personalized healthcare solutions.
The company will open a new technology hub in Bengaluru, which will serve as the nerve center for product innovation. This hub will develop AI and machine learning systems to:
- Recommend clinically approved alternative medicines that offer significant cost savings.
- Personalize patient journeys based on health profiles and past orders.
- Predict medicine demand and optimize supply chain operations.
By enhancing its tech capabilities, Truemeds plans to improve the accuracy of prescriptions, reduce wastage in the supply chain, and deliver a smoother user experience for patients nationwide.
Rapid Growth in Orders and Doctor Engagement
Truemeds has experienced rapid growth in the last year, more than doubling monthly order volumes. The platform now processes around 600,000 orders every month and works with 600 doctors daily.
The company focuses on serving patients with chronic health conditions such as diabetes, hypertension, and cardiovascular diseases. Its model promotes clinically equivalent, lower-cost generic medicines, helping patients save 50–70% on monthly medicine expenses.
By offering verified generic substitutes and maintaining doctor oversight on prescriptions, Truemeds builds trust among patients who are often skeptical about switching brands.
Investor Confidence in the Mission
Accel Partner Abhinav Chaturvedi praised Truemeds for combining technology with a clinically guided approach to make healthcare affordable. He highlighted the importance of tackling both affordability and accessibility for chronic care patients in India.
Sakshi Chopra, Managing Director at Peak XV Partners, emphasized that Truemeds addresses a large, underserved segment of the population in non-metro areas. She noted that the company’s omnichannel model and focus on essential medicine access have the potential to transform healthcare delivery for millions.
WestBridge Capital and Info Edge Ventures also reaffirmed their confidence by increasing their investments in the Series C round, signaling their belief in Truemeds’ growth potential and operational execution.
Company Journey and Current Valuation
Founded in 2019 by Akshat Nayyar and Dr. Kunal Wani, Truemeds started with the mission to deliver high-quality, affordable medicines to every household in India. The company combined doctor consultations, smart product recommendations, and reliable delivery to build a strong base among chronic care patients.
With the latest Series C round, Truemeds has now raised approximately $135 million in total funding. Industry analysts estimate the company’s current valuation at over $400 million.
Strategic Use of Series C Funds
Truemeds’ management outlined three core priorities for deploying the fresh capital:
- Fulfillment Expansion
- Increase the network from 19 to 50 fulfillment centers.
- Focus expansion on high-demand, underserved non-metro areas.
- Launch diagnostic service pilots to integrate testing with medicine delivery.
- Technology and Talent
- Open a Bengaluru technology hub for engineering and product teams.
- Recruit experienced professionals to develop AI-powered recommendation engines and supply chain tools.
- Enhance personalization features for patients and streamline ordering processes.
- Market Leadership and Service Quality
- Continue to double order volumes year-on-year.
- Strengthen relationships with over 600 doctors.
- Expand awareness campaigns on the safety and efficacy of generic medicines.
Why Truemeds’ Model Stands Out
- Affordability Without Compromise: Patients save up to 70% on medicines without sacrificing quality or effectiveness.
- Tech-Driven Operations: AI and machine learning tools guide patients to the most cost-effective treatment options.
- Doctor Oversight: Every prescription undergoes review, ensuring clinical validity.
- National Reach with Local Focus: Expansion prioritizes regions that lack consistent access to pharmacies and healthcare facilities.
Challenges Ahead
While Truemeds has strong momentum, it faces several challenges:
- Regulatory Complexity: E-pharmacy and telehealth services operate under evolving legal frameworks in India, requiring constant compliance oversight.
- Competitive Pressure: Large players like Tata 1mg, PharmEasy, Netmeds, and Apollo continue to expand aggressively into the generic medicine market.
- Operational Execution: Scaling from 19 to 50 fulfillment centers in one year will require precise coordination, strong vendor relationships, and rigorous quality control.
- Path to Profitability: High growth must eventually translate into sustainable margins, especially in a price-sensitive segment like chronic care.
Next Steps for Truemeds
In the next 12–18 months, Truemeds will:
- Launch at least 31 new fulfillment centers, prioritizing Tier 2 and Tier 3 cities.
- Fully operationalize its Bengaluru tech hub, releasing new AI-driven features.
- Integrate diagnostic services into its telehealth platform, starting with four pilot cities.
- Continue patient education programs to build trust in generic medicines.
By executing these steps, Truemeds aims to become the most trusted and widely used platform for chronic care management in India.
Conclusion
Truemeds’ $85 million Series C round marks a major milestone in its mission to make healthcare affordable and accessible in non-metro India. The company’s strategy blends fulfillment expansion, advanced technology, and a doctor-led care model to meet the needs of millions of patients who struggle with high medical costs and limited access to pharmacies.
With strong backing from Accel, Peak XV Partners, WestBridge Capital, and Info Edge Ventures, Truemeds has the resources to triple its reach and cement its position as a leader in the e-pharmacy and telehealth space. The coming year will test its ability to scale quickly while maintaining service quality and building trust in the vast and competitive Indian healthcare market.
Also Read – What Is “Stealth Mode” and Does It Actually Help